Clinical Trial Update: Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports on the immunogenicity and reactogenicity of the trivalent measles-mumps-rubella vaccine Trivivac in healthy infants in Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• Trivivac (Measles, Mumps, and Rubella vaccine (trivalent))

Snippet

Sponsor: Queen Sirikit National Institute of Child Health | Conditions: Immunogenicity, Reactogenicity | Phase 2, Phase 3 | Status: UNKNOWN